Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension

Currently, 150 million people around the globe struggle with difficult-to-control or treatment-resistant arterial hypertension, and often times related complications,” said Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics. “The positive feedback from the FDA regarding our clinical development plan to advance firibastat into Phase III trials in the United States represents a key milestone in the execution of our strategic plan as presented in April 2018. As of today, we have diligently worked to meet these milestones that we have set forth and look forward to meeting the coming ones. The pivotal Phase III efficacy study of firibastat in difficult-to-treat or treatment-resistant arterial hypertension will thus start by the end of 2019 and its results will be available in the second half of 2021.

Read the press release